GC012F, Gracell Biotechnologies’ investigational dual FastCAR T-cell therapy, was safe and highly effective at eradicating cancer cells in people with high-risk, newly diagnosed multiple myeloma, according to preliminary findings from an ongoing Phase 1 trial. “We are thrilled to report that BCMA/CD19 dual targeting FasTCAR-T GC012F is showing…
Telo Genomics has teamed up with the Mayo Clinic to develop tests to help clinicians identify multiple myeloma (MM) patients at high risk of experiencing a relapse after treatment. The new research into such drug resistance assessment measures follows the ongoing development of a previous test to detect…
The China National Medical Products Administration (NMPA) has agreed to review an application for Equecabtagene autoleucel — the country’s first chimeric antigen receptor (CAR) T-cell therapy — for relapsed or refractory multiple myeloma. The CAR T-cell therapy, the first to be developed domestically in China, was awarded breakthrough…
Biohaven Pharmaceuticals has begun enrolling patients in its Phase 1a/1b trial testing the company’s antibody-recruiting molecule (ARM) called BHV-1100. The trial (NCT04634435) seeks to recruit 25 adults with newly diagnosed multiple myeloma who have minimal residual disease in first remission before a stem cell transplant. One patient…
Get regular updates to your inbox.